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ABSTRACT 
Pancreatic cancer remains one of the poorest prognoses in medicine, with limited 
treatment options and 5-year patient survival of only ~7%. Activating mutations in the 
Kras proto-oncogene (KrasG12D) are nearly ubiquitous in human pancreatic cancer and are 
sufficient to initiate precancerous pancreatic intraepithelial neoplasia (PanINs) when 
expressed in adult acinar cells of mice. KrasG12D-driven PanINs normally take months to 
form, which lead to the hypothesis that acinar differentiation determinants may have an 
inhibitory effect on PanIN formation and subsequent cancer initiation. While targeted 
drugs that promote cell differentiation are curative in blood cancers like acute 
promyelocytic leukemia, there is currently minimal evidence suggesting that cell 
differentiation could play a role in limiting or stopping solid tumor growth. This 
dissertation aims to test whether loss of acinar differentiation, mediated through the 
transcription factor Ptf1a, is necessary and/or sufficient to initiate the early stages of 
pancreatic cancer. Using mouse genetics, we demonstrate that loss of Ptf1a alone is 
sufficient to promote acinar-to-ductal reprogramming and a cancer-like gene expression 
profile that is conducive to inflammation and Kras-dependency. As a result, Ptf1a-
deficient acinar cells are rapidly transformed into PanINs in the presence of oncogenic 
KrasG12D. Consistent with PanINs acting as precursor lesions to invasive pancreatic cancer, 
we demonstrate that loss of Ptf1a allows for rapid progression to carcinoma in situ and 
mortality from invasive pancreatic cancer in an established mouse model of disease. 
iv 
These data confirm that loss of acinar cell identity hastens tumor development 
independently of canonical tumor suppressor loss. In contrast, a novel mouse line that 
sustains Ptf1a expression during pancreatic cancer initiation eliminates formation of 
KrasG12D-driven precancerous PanINs. Perhaps most strikingly, reintroduction of Ptf1a into 
established precancerous PanINs reverts them to primitive acinar cells. Our findings 
therefore suggest that loss of acinar cell differentiation is required for pancreatic cancer 
origination and progression. This dissertation is among the first studies demonstrating 
that a cell differentiation program can prevent and reverse premalignant solid tumor cells 
in vivo and thus introduces a novel paradigm for solid tumor prevention and treatment. 
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 Cancer, at its essence, is uncontrolled proliferation and migration of cells that 
have lost a normal identity. What causes cancer initiating cells to emerge, however, is a 
question that has puzzled researchers for decades. Several hypotheses exist about the 
origination of cancer cells in different tissues. In organs with high cell turnover, such as 
the intestine, skin, and blood, accumulation of mutations and epigenetic changes in 
resident stem cells are thought to lead to their emergence as cancer propagating cells. 
Given a stem cell’s capacity for proliferation, this is an attractive hypothesis and has been 
experimentally validated. For example, when cancer causing mutations are engineered 
into the stem cells of the intestinal crypt, they give rise to precancerous polyps, 
resembling human disease (Barker et al., 2009). This hypothesis, however, does not 
explain why organs that are largely quiescent and do not have yet-identified stem cells 
populations, are so prone to cancer. Cancers from one such organ, the liver, for example, 
are the second leading cause of cancer-related death worldwide 
(https://www.cdc.gov/cancer/international/statistics.htm). How then could cancer be 
propagated from other, mature cells types? What confers growth advantages to 
differentiated cells that transform into cancer? Are mutations in oncogenes or tumor 
suppressors sufficient to transform differentiated cells and initiate cancer? My 
dissertation work utilizes the pancreas, another quiescent organ, and pancreatic ductal 
adenocarcinoma (PDAC) initiation as a model to study how fully differentiated cells can 
give rise to cancer. Our data suggest that loss of the transcriptional programs that confer 
cell identity might be the crucial and rate-limiting step leading to the emergence of 
tumor-initiating cells, regardless of mutation burden.  




medicine; while the disease only accounts for 3.1% of all new cancer cases in the USA, it 
causes 7.0% of all cancer deaths (seer.cancer.gov). The median survival with 
chemotherapy treatment is only ~9 months and fewer than 7% of patients live longer than 
5 years after diagnosis (Ryan et al., 2014; Von Hoff et al., 2013). Several factors 
contribute to this poor prognosis: for one, localized tumors are often asymptomatic and 
this issue is compounded by the lack of screening tests that can detect advanced but pre-
invasive lesions. Consequently, patients often present to clinics with metastatic disease, 
which is incurable. Obtaining sustained remission is rare even in patients with completely 
resected primary tumors, and approximately 70% of these patients succumb to recurrent 
illness. While the clinical course of disease is rapid, recent studies suggest that PDAC has 
an insidious onset: quantitative analysis of the genetic evolution of PDAC suggests it 
takes over 15 years from initiating mutation (usually in the proto-oncogene Kras, 
discussed below) to formation of metastatic cancer (Yachida et al., 2010). Understanding 
how the disease originates and evolves over this period could provide avenues for 
detection and therapeutic intervention, which might stop the disease before it 
metastasizes and becomes “incurable.” 
 For the reasons described above, studying PDAC initiation in humans is difficult. 
However, much insight has been gained from genetically engineered mouse models 
(GEMMs), which have been refined over the years to recapitulate many of the hallmarks 
of human PDAC initiation and progression (Murtaugh, 2014). Mouse and human 
pancreata are similar in histology and function; in both species, the adult pancreatic 
epithelium is largely quiescent and is comprised of several different cell types, including 




such as lipases and proteases, which are carried in an inactive state to the duodenum 
through a tubular network of duct cells. Together, acinar and duct cells comprise the 
exocrine pancreas from which PDAC arises. Notably, PDAC is thought to arise through a 
classic progression sequence, where mutations in the epithelium give rise to pre-
cancerous lesions termed pancreatic intraepithelial neoplasia (PanINs) (Hruban et al., 
2000; Morris et al., 2010b). PanINs evolve as they accumulate additional mutations and 
can eventually become invasive. Desmoplasia, a fibroinflammatory reaction to the 
mutating epithelium, increases with mutational burden and eventually forms the tumor 
stroma. 
 The defining mutational event in >90% of human PDAC cases is a single base 
substitution in the proto-oncogene KRAS (KrasG12D or KrasG12V) (Almoguera et al., 1988; 
Bailey et al., 2016; Maitra and Hruban, 2008; Waddell et al., 2015). The KRAS gene 
encodes a small GTPase signaling protein, which propagates a pro-proliferative signaling 
cascade in response to mitogen stimulation. Mutational events in cancer lock the KRAS 
protein in an activated, GTP-bound state, which allows for continuous propagation of 
pro-proliferative signaling through ERK and other pathways (di Magliano and Logsdon, 
2013). It is worth noting that RAS molecules are notoriously hard to drug, and targeting 
its major downstream effectors produces unfortunate side-effects in patients (Collins and 
Pasca di Magliano, 2013; McCormick, 2015). Thus, there is a great interest in 
understanding how RAS proteins intersect with other, targetable cellular pathways. While 
most precancerous PanINs lack the full mutational spectrum of invasive PDAC, they 
almost universally harbor one of these KRAS alterations, suggesting that KRAS mutation 




Maitra and Hruban, 2008). But which exocrine cells sustain an initial genetic “hit” in 
KRAS to initiate PDAC? 
 In the early 2000s, a first generation of transgene-based GEMMs were developed 
to identify the cell of origin of PDAC. Because the epithelium of PDAC resembles 
pancreatic duct cells, it was long hypothesized that ducts must be the cell of origin of 
PDAC. However, driving KrasG12V expression with the promoter of the duct-specific 
gene Cytokeratin-19 (Krt-19) had no significant effect on pancreatic morphology, 
producing only a mild inflammatory response without ductal dysplasia (Brembeck et al., 
2003). In contrast, expressing oncogenic KrasG12D under the control of the acinar-specific 
Elastase1 (Ela1) promoter lead to the formation of lesions with mixed acinar and ductal 
characteristics (Grippo et al., 2003). While these mixed lesions did not directly resemble 
human PanINs (Grippo et al., 2003; Hruban et al., 2006), these studies were among the 
first to indicate that duct-like tumor precursors might arise from acinar cells. 
 The GEMMs described above, however, had shortcomings that prevented 
definitive conclusions. For one, over-expressing oncogenic Kras can lead to cellular 
senescence – a problematic phenotype when studying cancer (Serrano et al., 1997). 
Another concern is that the Ela1 promoter might not be active in transformed cells or 
PanINs, as cells comprising these structures do not express Elastase1 or any other acinar-
specific genes. Therefore, the expression of oncogenic Kras might be transient in the 
lesions observed by Grippo and colleagues, explaining the mixed acinar and ductal 
phenotype (Collins et al., 2012; Grippo et al., 2003). These issues were partially solved 
by the laboratories of Tyler Jacks and Mariano Barbacid with the construction of 




(Guerra et al., 2003; Tuveson et al., 2004). These two alleles have a similar design: both 
contain a polyadenylation “STOP” cassette, flanked by loxP sites, upstream of a mutation 
in exon 2 that changes the Gly12 codon to aspartic acid or valine (KrasLSL-12D or KrasLSL-
G12V [LSL = loxP-STOP-loxP]). In the absence of Cre-recombinase, the STOP cassette 
prevents the expression of oncogenic Kras. However, when an active Cre enzyme is 
present, it removes the transcriptional STOP signal and allows for the permanent 
expression of oncogenic Kras at the endogenous level. Importantly, these alleles do not 
promote the senescence phenotype associated with RAS overexpression (Guerra et al., 
2003; Serrano et al., 1997; Tuveson et al., 2004). 
 To direct expression of KrasG12D exclusively to the pancreas, cancer researchers 
have employed tools from the developmental biology community. Using the Pdx1 
promoter (Pdx1-Cre) (Gu et al., 2002) or the endogenous Ptf1a locus (Ptf1aCre) 
(Kawaguchi et al., 2002) to express Cre allows for recombination of the Kras locus in 
progenitor cells of the early embryonic pancreas, thus inducing expression of oncogenic 
Kras throughout the pancreatic epithelium. The combination of Pdx1-Cre and KrasLSL-
G12D is currently the most commonly used model of PDAC and is often referred to as the 
“KC” (Kras, Cre) mouse. As its wide usage would suggest, the KC mouse model 
recapitulates many hallmarks of human disease, most prominently including progressive 
disease development. Low grade PanIN-1 lesions are first observed in pancreata of KC 
mice at ~2 months age, albeit infrequently (Aguirre et al., 2003; Hingorani et al., 2003). 
These lesions become more numerous and dysplastic with age; however, they tend not to 
progress to bona fide PDAC unless additional mutations/deletions in tumor suppressor 




2006; Hingorani et al., 2003; Hingorani et al., 2005). While the KC mouse is an 
extremely useful model for PDAC research, it still has shortcomings. For one, pancreatic 
cancer is primarily a disease of aging; thus, activation of oncogenic Kras early in the 
embryonic pancreas may not recapitulate the true disease course. Second, the expression 
of oncogenic Kras throughout the pancreatic epithelium precludes identifying the cell of 
origin of PanINs and PDAC. Finally, the ubiquitous activation of KrasG12D in the 
pancreatic epithelium is unlike human disease, where mutations likely occur sporadically 
in random, isolated cells.  
 How could these issues be addressed? The introduction of lineage-specific, 
inducible Cre lines led to a series of elegant studies revealing that acinar cells are a 
primary cell of origin of both PanINs and PDAC. To test whether acinar cells could give 
rise to PanINs, the Elastase1 promoter (Ela-CreERT), or the endogenous Mist1 
(Mist1CreERT2) or Ptf1a (Ptf1aCreERT) loci are used to express a Cre-recombinase fused to a 
modified form of the estrogen receptor (ER) ligand binding domain. This Cre-ER 
complex remains inactive in the cytoplasm until tamoxifen (TM) is administered. Upon 
TM treatment, Cre enters the nucleus and recombines the KrasLSL-G12D locus, inducing 
expression of oncogenic KrasG12D specifically in adult acini. In 2008, our lab, along with 
Drs. Steven Leach, Stephen Konieczny and Anirban Maitra used these models to 
demonstrate that acinar-specific KrasG12D lead to the spontaneous formation of mouse 
PanINs in <2 months (De La O et al., 2008; Habbe et al., 2008). Consistent with the 
PanIN-PDAC progression model, the lab of Craig Logsdon went on to establish that 
acinar-specific activation of KrasG12D and simultaneous deletion of the tumor suppressor 




(Ji et al., 2009). These studies were the first to definitively show that acinar cells could 
serve as a cell of origin for PDAC, despite the ductal phenotype of PanINs and 
carcinoma.  
 Are duct cells also capable of giving rise to PanINs and subsequent PDAC? To 
answer this question, the lab of Maike Sander developed a Sox9-CreER BAC transgenic 
line, which could be utilized to express KrasG12D specifically in adult duct cells (Kopp et 
al., 2011). While they confirmed that KrasG12D expression in acinar cells readily gives 
rise to PanINs, duct cells (including centroacinar cells that occupy the junction between 
acinus and duct) were almost completely resistant to transformation by KrasG12D, even 
after more than a year (Kopp et al., 2012). These studies strongly suggest that acinar cells 
are the principal cell of origin in the PanIN-to-PDAC progression sequence. Interestingly, 
over the past year, the lab of Jen Bailey demonstrated that duct cells with KrasG12D and 
homozygous point mutations in Tp53 (p53R172H, a variant often seen in human cancer) 
can form invasive PDAC (Bailey et al., 2015). These carcinomas arise rapidly and do not 
seem to be associated with PanINs. But, human PanINs rarely contain even heterozygous 
Tp53 mutations, suggesting that the PanIN-to-PDAC model is exclusively an acinar 
derived entity (Hosoda et al., 2017). 
 In all GEMMs described above, acinar cell transformation by KrasG12D is 
relatively inefficient; that is, KrasG12D is necessary but not sufficient for PanIN formation 
even when ubiquitously expressed in the acinar cell population. In fact, most acinar cells 
expressing KrasG12D remain resistant to transformation for the entire life of the animal. 
What then inhibits KrasG12D-mediated transformation in acinar cells? One intriguing 




the reprogramming of acini into PanINs (Murtaugh, 2014; Rooman and Real, 2012). 
Central to the acinar differentiation program is the PTF1 complex, which consists of three 
transcription factors: Rbpj-L, a member of the Suppressor of Hairless transcription factor 
family; one of several ubiquitously-expressed bHLH E-proteins; and, forming a 
heterodimer with the E-protein, the bHLH factor pancreas-specific transcription factor 1a, 
or Ptf1a (Beres et al., 2006; Masui et al., 2010; Rose et al., 2001). Importantly, Ptf1a 
regulates the expression of itself and other transcriptional mediators, such as Nr5a2 and 
Mist1, with which it cooperates to control transcription of secretory proteins and 
zymogens, exocytosis components, and regulators of endoplasmic reticulum stress – 
functions all crucial to normal acinar cell function and homeostasis (Hess et al., 2016; 
Holmstrom et al., 2011; Jiang et al., 2016; Kim et al., 2015; Masui et al., 2008). 
 The hypothesis that this transcriptional network could inhibit Kras-mediated 
transformation is born out of both histological and genomic data. For example, when 
KrasG12D and Notch signaling synergistically reprogram acinar cells into PanINs, Ptf1a is 
rapidly lost (De La O et al., 2008). This results in complete reprogramming of the cell, 
represented by a shift away from acinar-specific gene expression and upregulation of 
ductal genes and mucin production (Habbe et al., 2008). Additionally, genome-wide 
association studies identified PDAC risk-associated single nucleotide polymorphisms 
(SNPs) in NR5A2, a protein that promotes acinar-specific gene expression in 
collaboration with Ptf1a (Holmstrom et al., 2011; Li et al., 2012; Petersen et al., 2010). 
Consistent with these data, when loss of loss of Nr5a2 is compounded with KrasG12D 
activation in acinar cells, PanIN formation is dramatically increased (Flandez et al., 2014; 




might be a key factor contributing to KrasG12D-mediated PanIN initiation and subsequent 
PDAC formation. Interestingly, mouse Nr5a2 is also required for resolution of organ 
injury following acute pancreatitis, highlighting the tension between acinar cell 
differentiation and inflammation (von Figura et al., 2014). 
  Pancreatitis itself is one of the most significant risk factors for PDAC 
development (Duell et al., 2012; Lowenfels et al., 1993). Several studies, from our lab 
and others, have translated this human epidemiological data into experimental 
mechanism; for example, pharmacological induction of pancreatitis in mice with acinar 
mutant Kras greatly accelerates the number and severity of PanINs (De La and Murtaugh, 
2009; Guerra et al., 2007; Morris et al., 2010a). Interestingly, progenitor-like gene 
expression and downregulation of acinar-specific genes is a transient hallmark of 
pancreatic regeneration following acute injury (Jensen et al., 2005; Karki et al., 2015). 
This includes downregulation of Ptf1a target genes, and increased expression of the 
progenitor markers Pdx1 and Sox9 as well as upregulation of Notch signaling 
components (Jensen et al., 2005; Karki et al., 2015; Murtaugh et al., 2003). Could this 
brief loss of cell identity be co-opted by KrasG12D leading to PanIN formation? These 
findings ultimately suggest that even a brief window of acinar dedifferentiation creates an 
intermediate cellular phenotype that is uniquely sensitive to Kras-mediated 
transformation. 
 Based on these findings, we hypothesized that loss of Ptf1a, the master regulator 
of acinar cell identity, is a crucial and rate-limiting step in PanIN/PDAC formation. 
Through my dissertation project, we have demonstrated that loss of Ptf1a alone is 




that of RAS-addicted human cancer cells. Consequently, deletion of Ptf1a accelerates 
both PanIN and invasive PDAC formation in the presence of KrasG12D (Krah et al., 2015). 
Our unpublished results suggest that sustaining Ptf1a expression prevents PanIN 
formation, and that reintroduction of Ptf1a into established PanINs leads to 
redifferentiation of dysplastic cells. Taken together, the data presented here establish a 
role for cell identity factors as a novel class of “noncanonical” tumor suppressor genes, 
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PANCREATIC ACINAR CELL DEDIFFERENTIATION  
ABROGATES ANTI-INFLAMMATORY AND  




 Pancreatitis-mediated injury stimulates Kras-mediated tumorigenesis in mouse 
models of pancreatic ductal adenocarcinoma (PDAC). We recently discovered that acinar 
cell dedifferentiation induced by Ptf1a deletion also promotes PDAC initiation. As we 
find that both injury and dedifferentiation are associated with inflammation, we 
hypothesized that tumorigenesis in these models could be alleviated by the anti-
inflammatory drug dexamethasone. While dexamethasone subdued tumor initiation 
induces by the combination of injury and oncogenic Kras, it paradoxically accelerated 
tumorigenesis in the context of Ptf1a deletion. Our data indicate that tumor-promoting 
inflammation induced by dedifferentiation is distinct from that induced by injury, and 





 Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal prognosis, 
partially due to limited treatment options. Activated Kras (KrasG12D), the major driver 
oncogene of PDAC, is currently “undruggable” and targeting its immediate downstream 
signaling molecules has debilitating side-effects. Therefore, using preclinical models of 
PDAC to identify and modulate other targets that stall or reverse early disease is of the 
utmost importance (Ryan et al., 2014).  
 Expressing activated KrasG12D exclusively in murine acinar cells is sufficient for 
preneoplastic pancreatic intraepithelial neoplasia (PanIN) formation, albeit at a slow pace 
(De La et al., 2008; Kopp et al., 2012). Several recent studies suggest that the 
transforming ability of Kras is greatly enhanced by extrinsic inflammatory signals (di 
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Magliano and Logsdon, 2013). This connection between acinar-intrinsic mutant Kras and 
acinar-extrinsic inflammation appears to be bidirectional; high levels of inflammatory 
signaling, as seen in caerulein-induced pancreatitis, activate the transforming ability of 
Kras, and high Kras activity is itself sufficient to induce rampant pancreatic inflammation 
(Daniluk et al., 2012; De La and Murtaugh, 2009; di Magliano and Logsdon, 2013; 
Huang et al., 2014; Ji et al., 2009). The positive feedback loop that emerges between 
inflammation and oncogenic Kras activity provides an attractive therapeutic target. 
Indeed, broadly inhibiting inflammation with the corticosteroid dexamethasone (DEX) 
preserves epithelial identity by preventing epithelial-to-mesenchymal transition and 
inhibits tumor cell dissemination in the well-characterized “KPC” (KrasG12D, mutant p53, 
Cre) model of PDAC (Rhim et al., 2012). Understanding how inflammatory signals 
enhance the transforming ability of KrasG12D will be essential to translating these findings 
into the clinic.  
 
Results 
 While the microenvironment provides extrinsic inputs to amplifying KrasG12D 
activity, cell-intrinsic factors, such as acinar differentiation determinants, act to prevent 
oncogenic transformation. When the acinar-specific transcription factor gene, Ptf1a, is 
deleted from exclusively acinar cells (Ptf1a cKO), spontaneous dedifferentiation, like that 
seen in pancreatitis, is rapidly induced (Hoang et al., 2016; Krah et al., 2015). Ptf1a cKO 
pancreata are also dramatically sensitized to KrasG12D-mediated PanIN formation, with 
persistent leukocyte infiltration and fibrosis, similar to that seen when acinar-KrasG12D mice 
are given caerulein-induced pancreatitis (Figure 4.1A-I) (De La and Murtaugh, 2009; 
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Kopp et al., 2012; Krah et al., 2015). Based on these phenotypic similarities, we 
hypothesized that broadly inhibiting inflammation with DEX would suppress the rapid 
transformation seen in both KrasG12D/caerulein and KrasG12D/Ptf1a cKO mouse models. 
Additionally, these experiments allowed us to test the epistatic relationship between 
inflammatory signals and acinar dedifferentiation during early PDAC initiation (Figure 
4.1J, K). 
 To test these hypotheses, we developed two treatment regimens that generate a 
similar phenotype over an 18-day period. In this protocol, mice received either a daily 
injection of 10 mg/kg DEX or saline vehicle, beginning simultaneously with tamoxifen 
treatment (Figure 4.2). Kras/caerulein mice (genotype: Ptf1aCreERT/+; KrasLSL-G12D/+, Figure 4.2A) 
were administered tamoxifen (TM) on three consecutive days, before receiving caerulein 
treatment on days 7 and 8. Mice were sacrificed for histologic examination 10 days after 
the first caerulein administration (Figure 4.2B). In contrast, Kras/Ptf1a cKO mice were 
administered a single pulse of TM with no further intervention until sacrifice 18 days 
later (Figure 4.2B). The resulting histologic phenotypes exhibit widespread acinar cell 
transformation, fibrosis, and leukocyte infiltration, but minimal mature PanIN formation, 
which allowed us to evaluate the early stages of PDAC initiation and any 
acceleration/deceleration of disease.  
 Using this protocol, we found that DEX-treated Kras/caerulein pancreata 
exhibited reduced acinar cell transformation and a significant preservation of normal 
acinar tissue (Figure 4.3A-B, F), despite similar gross appearance and mass (Figure 
4.3E). Overall, inflammation was reduced in DEX-treated pancreata, but was still present 
in transforming and fully transformed areas. Fibrosis, a hallmark of PanIN initiation and 
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progression, was highlighted with Sirius red staining and revealed a reduction in fibrotic 
tissue in DEX-treated Kras/caerulein mice (Figure 4.3C-D). These results corroborate 
those obtained in the KPC model, and confirm that the tumor-promoting effects of 
pancreatitis are mediated by DEX-sensitive inflammatory mechanism. 
 In contrast, Kras/Ptf1a cKO mice treated with DEX retained no histologically 
normal acinar tissue compared to saline treated controls (Figure 4.3 G-H) and exhibited a 
surprising number of high-grade PanINs following our 18-day protocol (Figure 4.3H). 
While pancreata from DEX-treated animals had a significant reduction in edema and 
organ mass (Figure 4.3M), they also exhibited a dramatically increased PanIN burden 
(Figure 4.3N), which was confirmed with Alcian blue staining and 
immunohistochemistry for Claudin18 (Figure 4.3I-L). Regardless of treatment, however, 
Kras/Ptf1a cKO pancreata exhibited a severe fibroinflammatory response, as indicated by 
Sirius red staining (data not shown), which is consistent with our previous findings (Krah 
et al., 2015). 
 Based on these results, we hypothesized that forced acinar dedifferentiation, via 
Ptf1a deletion, establishes a unique inflammatory milieu that alters the response to DEX. 
To begin to test this hypothesis, we performed immunofluorescence for different immune 
cell types to examine their abundance and localization. Although we found abundant 
CD45+ leukocytes (primarily F4/80+ macrophages) in both models, these cells were 
decreased by DEX only in Kras/caerulein mice (Figure 4.4A-H). Regions of the pancreas 
in which amylase+ acinar cells were preserved by DEX treatment contained scant CD45+ 
leukocytes. In contrast to macrophages, the infiltration of CD3+ T-cells that wasobserved 
in both models was uniformly abolished by DEX treatment (Figure 4.4I-L, M). 
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Interestingly, CD8+ T-cells, which have an inhibitory effect on PanIN initiation and 
progression (Zhang et al., 2014), were completely ablated by DEX treatment in 
Kras/Ptf1a cKO pancreata (Figure 4.4N-O).  
Discussion 
Our data suggest the existence of distinct inflammatory infiltrates, one that 
includes T-cells and is DEX-sensitive, and another that includes F4/80+ cells 
(macrophages and/or other monocytes), that is DEX-resistant at least in the context of 
Ptf1a-deficient epithelium (Figure 4.5). As both macrophages and T-cells are required for 
PanIN formation (Liou et al., 2015; McAllister et al., 2014; Zhang et al., 2014), we 
propose the possibility that an initial phase of DEX-sensitive inflammation is responsible 
for propagating acinar cell dedifferentiation, which in turn triggers a second, DEX-
resistant phase that promotes bona fide PanIN development. Deletion of Ptf1a may 
effectively “skip” the first inflammatory phase, allowing the second phase inflammatory 
cells to infiltrate and rapidly induce PanINs. 
Importantly, our results highlight the dynamics of the PDAC microenvironment 
during different stages of tumor initiation and suggest that these changes may influence 
the response to commonly used anti-inflammatory drugs. Consistent with previous 
studies, we found that DEX treatment preserves normal pancreatic architecture in 
differentiation-competent epithelium, which suggests that the inflammatory signals 
inhibited by DEX act upstream of acinar cell identity loss (Rhim et al., 2012). However, 
our results also suggest that other inflammatory signals, perhaps from 
macrophages/monocytes, act downstream of dedifferentiation to drive PanIN formation. 
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These signals are impervious to DEX treatment and act rapidly to further transform 
dedifferentiated cells. Identifying and inhibiting the signals that act upstream and 
downstream of cell identity changes will be crucial in treating PDAC that is associated 
with chronic inflammation (pancreatitis), and in patients with other risk factors that 
generate systemic inflammation, such as obesity and smoking (Krah and Murtaugh, 
2016). As targeting the tumor microenvironment has emerged as a new anticancer 
approach, particularly in tumors whose cell-autonomous drivers are hard to directly 
target, our results merit further investigation. 
 We hypothesize that the first “wave” of inflammation is T-cell-dependent and 
mediates the initial steps in acinar cell transformation. To test this hypothesis, our lab will 
determine if IL-17a signaling from CD4+ T-cell is required for PanIN formation in the 
absence of Ptf1a. Ablation of CD4+ T-cells, which includes T-helper and TH17 cells, has 
been shown to inhibit PanIN development in the Kras/caerulein model (McAllister et al., 
2014; Zhang et al., 2014). The results described in this thesis, however, suggest that 
blocking T-cell infiltration with DEX does not prevent PanIN development in the 
Kras/Ptf1a cKO model; this implies that the major role for T-cells and IL-17 signaling 
during PanIN initiation is to promote acinar de-differentiation. This could be tested in 
two ways:  first, CD4+ T-cells could be depleted in both the Kras/caerulein and 
Kras/Ptf1a cKO by weekly i.p. injection of purified GK1.5 anti-CD4 monoclonal 
antibody (BioXCell), as previously described (McAllister et al., 2014). Second, we could 
cross both Kras/caerulein and Kras/Ptf1a cKO mice onto an Il17a-/- background and 
determine whether this influences PanIN burden in both models (Nakae et al., 2002). 
What results would be expected if CD4+ T-cells act to cause dedifferentiation? If either 
 65 
of these inputs (CD4+ T-cells or IL-17a) acts strictly at the dedifferentiation stage, then 
we expect that it should be dispensable for PanIN formation in a Ptf1a cKO background. 
However, if these cells/signals promote progression to the PanIN stage, we could expect 
to observe dedifferentiation lesions without hallmarks of progression (i.e., no Alcian blue+ 
lesions, or Claudin18+ lesions) (Krah et al., 2015). 
 It will also be necessary to test whether macrophage-derived IL-6 promotes 
PanIN development independent of differentiation state. Given the abundance of 
macrophages present in both our experimental models, we hypothesize that macrophage-
derived IL-6 is required to fully activate KrasG12D and drive dedifferentiated Ptf1a-null 
acini toward a PanIN fate. This represents the theoretical second “wave” of inflammation 
that is required to progress ADM into PanINs. To test whether macrophages themselves 
are required for ADM-to-PanIN progression, we will use gadolinium (III) chloride 
(GdCl3, Sigma), which specifically kills macrophages due to their phagocytic activity 
(Hardonk et al., 1992). GdCl3 will be administered in both Kras/caerulein and Kras/Ptf1a 
cKO models and we will quantify the PanIN formation and verify macrophage depletion.  
To determine whether Ptf1a loss abrogates the need for IL-6, we propose to cross Kras 
and Kras/Ptf1a cKO mice onto an Il6-/- background, which has previously been shown to 
dramatically curtail PanIN development (Kopf et al., 1994; Lesina et al., 2011). We 
hypothesize that macrophage derived IL-6 is required after dedifferentiation for Kras-
induced PanIN formation; therefore, blocking either macrophages or IL-6 should halt 
tumor initiation at the ADM stage, even in Ptf1a cKO pancreata. Such a result would 
encourage further development of this approach for treatment of tumors that have 
progressed beyond the point of redifferentiation. However, if PanINs do form, despite 
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macrophage or IL-6 depletion, it would infer that macrophage and IL-6 signaling is 
require solely to drive acinar metaplasia, and may not be a viable target in advanced 
PDAC. As we anticipate that the future of PDAC therapies will involve not only 
chemotherapy, but manipulation of differentiation, inflammation, and antitumor 
immunity, these results have the potential to inform future treatment decisions.  
Materials and Methods 
Mice 
All of the following mouse alleles utilized in this study have been previously 
described in the referenced publications: Ptf1aCreERT (Ptf1atm2(cre/ESR1)Cvw),(Kopp et al., 2012) 
Ptf1alox,(Hoang et al., 2016; Krah et al., 2015) and KrasLSL-G12D (Krastm4Tyj)(Hingorani et al., 
2003). To activate CreERT-mediated recombination, mice were administered 0.25 mg/g 
body weight tamoxifen (Sigma, St. Louis, MO) dissolved in corn oil by oral gavage (see 
Figure 4.2 for experimental schematics). All experiments were performed per 
institutional and NIH guidelines. 
Dexamethasone treatment 
KrasG12D mice (genotype: Ptf1aCreERT/+; KrasLSL-G12D/+) and KrasG12D; Ptf1a cKO mice 
(genotype: Ptf1aCreERT/lox; KrasLSL-G12D/+) were injected intraperitoneally (i.p.) with either 
dexamethasone (10 mg/kg/day) or saline daily for 17 days (Rhim et al., 2012). Mice were 
sacrificed on day 18 of our protocol, and pancreata were excised for histological analysis. 
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Tissue processing and histology 
Following euthanasia, pancreata were dissected into chilled phosphate buffered 
saline (PBS) and weighed, prior to being separated into several fragments for paraffin and 
frozen histology. Tissues were fixed for paraffin embedding in zinc-buffered formalin (Z-
FIX; Anatech, Battle Creek, MI) at room temperature overnight and were processed into 
Paraplast Plus (McCormick Scientific). Frozen specimens were fixed in 4% 
paraformaldehyde/PBS at 4°C for 1–2 hours, settled into 30% sucrose in 1x PBS, 
followed by processing into Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, 
CA). Both Paraffin and frozen sections were cut at thickness of 6 μm and collected 
sequentially across multiples slides with at least 100-μm spacing between individual 
sections on a single slide; this allowed us to gain a representative picture of the histology 
throughout the entire organ on a single slide.  
H&E staining, immunohistochemistry, and immunofluorescence were performed 
following standard procedure from our previously published papers. All IHC slides were 
subjected to high-temperature antigen retrieval (Vector Unmasking Solution; Vector 
Laboratories, Burlingame, CA) prior to primary antibody application. Primary antibodies 
utilized in this study are listed in Table 4.1. Vectastain reagents and diaminobenzidine 
(DAB) substrate (Vector Laboratories) were used for IHC. Immunofluorescence slides 
were counterstained with DAPI and mounted in Fluoromount-G (Southern Biotech) and 
photographed on an Olympus IX71 microscope using MicroSuite software (Olympus 
America, Waltham, MA). Images were taken with matching exposure times and identical 
adjustments were performed in Adobe Photoshop between genotypes and treatment 
groups. Sirius red staining was performed on frozen sections, which were fixed for 1 hour 
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at 55C in Bouin’s fixative. Specimens were washed in dH2O and stained for 1 hour in 
Picro-Sirius Red at room temperature. 0.5% acetic acid was used to rinse specimens after 
staining; slides were then dehydrated and equilibrated into xylene and mounted with 
Permount. Alcian blue staining was performed on paraffin sections which were washed 
for 10 minutes in 3% acetic acid prior to a 15-minute incubation in staining solution (1% 
Alcian blue in 3% acetic acid). Slides were subsequently washed in 3% acetic acid, 
dehydrated, and equilibrated to xylene before being mounted with Permount. All bright 
field images were acquired on an Olympus CX41 microscope using MicroSuite software. 
Caerulein treatment 
Acute pancreatitis was induced in KrasG12D mice (genotype: Ptf1aCreERT/+; KrasLSL-G12D/+) by 
administering hourly 0.1 μg/g i.p. injections of caerulein (Bachem, Torrance, CA) six 
times daily over two consecutive days. Negative controls were injected with saline 
vehicle alone (Jensen et al., 2005; Keefe et al., 2012; Kopp et al., 2012). In DEX treated 
animals, the daily DEX injection was administered following all 6 caerulein injections. 
Pancreata were harvested 10 days following the final injection and processed as described 
above.  
Quantifying PanIN burden 
To determine the surface area of Alcian blue stained pancreata, sections were 
photographed at 4x original magnification and photomerged in Adobe Photoshop. Area 
was determined using ImageJ software (NIH). The number of Alcian blue positive 
lesions was counted manually under the microscope and PanIN burden was calculated as 
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the total number of Alcian blue positive lesions per cm2 surface area. As previously 
described, we did not count metaplastic lesions that do not stain clearly with Alcian blue. 
To avoid double counting large or tortuous lesions, we scored no more than one lesion 
within an anatomically distinct pancreatic lobule, as previously described (De La et al., 
2008; Krah et al., 2015). All statistical analyses and graphs were made using Graphpad 
Prism 7. 
 
Scoring normal vs abnormal area 
 H&E and Sirius red stained slides were photographed at 4x original magnification 
and photomerged in Adobe Photoshop. Using these composite images, we over-layed a 
grid (1mm x 1mm) and quantified the number of square containing metaplastic areas of 
the pancreas versus areas that retained normal acinar cells using Adobe Photoshop. The 
proportion of diseased area was then calculated as a percentage of the entire section area 
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Figure 4.1. Phenotypic similarities in mouse models of pancreatic cancer initiation. 
H&E images from pancreata of mice expressing KrasG12D in acinar cells 8 weeks after 
induction (A), mice expressing KrasG12D in acinar cells three weeks after caerulein 
administration (B), and mice expressing KrasG12D and with simultaneous Ptf1a deletion 6 
weeks after induction (C). Immunofluorescence for amylase (acinar cells), CK19 (duct 
cells), and CD45 (leukocytes) (D-F), and Sirius red staining in mice of the same 
treatment groups (G-I). Immunofluorescent images are 20x and bright field images are 
40x original magnification. (J-K) Contrasting naïve models of the relationship between 
dedifferentiation and inflammation during KrasG12D-mediated acinar cell transformation.  
73 
Figure 4.2. Mouse alleles and experimental schematics. (A) KrasG12D mice contain an 
oncogenic KrasLSL-G12D allele which is can be activated by Cre mediated recombination, 
which removes the transcriptional stop cassette at the 5’ end of the allele. CreERT is 
expressed exclusively in acinar cells by driving expression from the endogenous Ptf1a 
locus. KrasG12D; Ptf1a cKO mice contain the same alleles and an additional Ptf1a “floxed” 
allele which can be excised by active Cre recombinase. (B) Experimental schematics for 






Figure 4.3. Differing responses to dexamethasone treatment in two models of PDAC 
initiation. Representative H&E and Sirius red images from KrasG12D pancreata with 
indicated treatment (A-D). Quantifications of pancreatic mass (E), and PanIN/fibrosis vs. 
normal histological area (F). H&E, Alcian blue, and Claudin-18 staining from KrasG12D; 
Ptf1a cKO pancreata with and without dexamethasone treatment (H-M). Arrowheads 
indicate Alcian blue positive lesions (I-J). Quantification of pancreatic mass (M), and 
PanINs per area (N).  
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Figure 4.4. Dexamethasone treatment depletes T-cell infiltration, but not 
macrophage presence, in KrasG12D; Ptf1a cKO pancreata. Immunofluorescence for 
acinar cell amylase, ductal CK19, DAPI, and either the pan-leukocyte marker CD45 (A-
D) or lineage-specific markers: F4/80+ macrophages (E-H), CD3+ T-cells (I-L), or CD8+ 
cytotoxic T-cells (N-O). Quantification of T-cell infiltration in indicated treatment 
groups; each color represent an individual biological replicate, with each technical 





Figure 4.5. Model diagram of inflammatory infiltration during PDAC initiation. Our 
data suggest that acinar cell dedifferentiation plays a key role in the recruitment of tumor-
promoting immune cells during KRAS-induced PDAC initiation, as well as in the 
response of KRAS-mutant epithelium to the signals produced by those cells. Our data 
suggest the existence of two distinct inflammatory responses involved in PDAC 
initiation, one that is DEX sensitive and PTF1A-regulated, and another that cannot be 
inhibited by DEX and is not directly related to PTF1A. We hypothesize that loss of 
PTF1A abrogates the requirement for CD4+ T-cells and IL-17.  DEX-mediated inhibition 
of cytotoxic T-cells may also allow PanIN maturation, once acinar cells have undergone 






















Table 4.1. Primary antibodies utilized in this study 
 
Antigen Species Source Catalog # Dilution used 
Amylase Sheep BioGenesis 0480-0104 1:1000 
Cd45 Rat eBioScience 14-0451-82 1:2000 
Cd3 Rat AbD serotec MCA500G 1:1000 
Cd8a Rat eBioScience 14-0808-80 1:1000 
Claudin-18 Rabbit Invitrogen 700178 1:2000 
Cytokeratin-19 Rabbit Abcam AB133496 1:5000 




IN VIVO INHIBITION AND REVERSION OF PANCREATIC 





Pancreatic cancer remains one of the worst prognoses in medicine, with a 5-year 
patient survival of only ~7%. Activating mutations in Kras are nearly ubiquitous in 
human pancreatic cancer and are sufficient to initiate precancerous pancreatic 
intraepithelial neoplasia (PanINs) when expressed in adult acinar cells of mice. PanINs 
normally take months to form, but can be rapidly induced by loss of acinar 
differentiation, suggesting that loss of mature cell identity is a rate-limiting step in tumor 
initiation. Here, we show that enforced acinar differentiation, mediated through the 
transcription factor Ptf1a, can inhibit and even reverse the early stages of pancreatic 
cancer. Using an established mouse model of this disease, we show that loss of Ptf1a 
allows for rapid progression to invasive and lethal adenocarcinoma, confirming that loss 
of acinar cell identity hastens tumor development independent of canonical tumor 
suppressor genes. Conversely, sustaining Ptf1a expression during pancreatic cancer 
initiation eliminates formation of Kras-driven PanINs. Additionally, reintroduction of 
Ptf1a into established PanINs reverts them to primitive acinar cells. To our knowledge, 
this is the first study establishing that a cell differentiation program can prevent and 
reverse oncogenic transformation in vivo and thus introduces a novel paradigm for solid 
tumor prevention and treatment. 
Introduction 
With a 5-year survival of only ~7%, pancreatic ductal adenocarcinoma (PDAC) is 
one of the most aggressive solid tumors and urgently requires novel interventions (Siegel 
et al., 2016). While the median survival of ~8 months suggests a rapid disease course, 
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mathematical modeling of human tumor mutation data suggests that PDAC has a gradual 
onset, requiring over 15 years to progress from initial genetic mutation to metastatic 
disease (Yachida et al., 2010). This window of time could allow for early detection, 
prevention and treatment before tumors metastasize and become incurable. Thus, 
understanding the way disease initiates and progresses is of the utmost importance. 
While studying early PDAC in humans has been difficult due to the advanced 
presentation of disease, genetically engineered mouse models (GEMMs) have provided 
insight into the biology of PDAC initiation. The proto-oncogene Kras is mutated in over 
90% of human PDAC cases (Bailey et al., 2016) and represents a driver mutation in 
GEMMs (Hingorani et al., 2003). Activated mutant Kras is required to initiate and 
maintain precancerous pancreatic intraepithelial neoplasia (PanINs) and drive progression 
to invasive PDAC; however, targeting mutant Kras directly, or RAS signaling, has been 
met with little clinical success (Collins et al., 2012a; Collins et al., 2012b; Collins and 
Pasca di Magliano, 2013; di Magliano and Logsdon, 2013; McCormick, 2015). While the 
majority of PanINs do not harbor mutations in genes other than Kras (Hosoda et al., 
2017), progression to invasive cancer generally requires mutation in tumor suppressor 
genes, such as TP53, DPC4/SMAD4, INK4A, CDKN2A (Ryan et al., 2014). Accordingly, 
mutation or deletion of these tumor suppressors in conjunction with KrasG12D expression in 
pancreatic GEMMs recapitulates invasive PDAC with nearly 100% penetrance (Aguirre 
et al., 2003; Bardeesy et al., 2006; Hingorani et al., 2005; Whittle et al., 2015). 
While the epithelial cells that comprise both PanINs and PDAC tumors resemble 
pancreatic duct cells, our lab and others have demonstrated that precancerous PanINs 
arise, almost exclusively, from mature acinar cells (Bailey et al., 2015; De La et al., 2008; 
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Habbe et al., 2008; Kopp et al., 2012). The transforming ability of KrasG12D, though, is still 
relatively inefficient, even when it is expressed ubiquitously in acinar cells throughout 
the pancreas. However, caerulein-induced pancreatitis, which mimics a well-known 
human risk factor for PDAC development (Lowenfels et al., 1993), rapidly transforms 
Kras-mutant acinar cells into PanINs (De La and Murtaugh, 2009; Guerra et al., 2007; 
Kopp et al., 2012). Pancreatitis itself is sufficient to induce transient metaplasia of wild-
type acinar cells, in which they assume a ductal morphology and downregulate key 
regulators of acinar identity in favor of a progenitor-like gene expression profile (Jensen 
et al., 2005; Karki et al., 2015). Of note, duct cells are largely resistant to pancreatic 
cancer initiation, as pancreatitis administered to mice with KrasG12D-expressing duct cells 
generates minimal PanIN formation (Kopp et al., 2012). 
Together, these observations lead to the hypothesis that loss of acinar 
differentiation determinants might inhibit PDAC initiation by restraining the 
transforming ability of oncogenic Kras (Murtaugh, 2014; Rooman and Real, 2012). 
Indeed, deletion of any of three key transcription factors that coordinate acinar cell target 
gene programs, in conjunction with activated Kras, is sufficient to initiate rapid and 
robust PanIN formation, similar to that seen in pancreatitis (Flandez et al., 2014; Krah et 
al., 2015; Shi et al., 2013; von Figura et al., 2014). Deletion of the master regulator of 
acinar cell identity, Ptf1a, alone, causes metaplasia and induces a PDAC-like, Kras-
permissive gene expression profile (Krah et al., 2015). In vitro, E47, a partner 
transcription factor of Ptf1a, can return pancreatic cancer cell lines to a quiescent state 
and induce acinar-specific gene expression (Kim et al., 2015). We therefore hypothesized 
that maintaining Ptf1a expression in vivo would restrain PanIN formation and 
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progression. We additionally sought to determine the plasticity of precancerous cells in 
the pancreas: can Ptf1a reprogram established PanINs back to benign acinar cells?  
 In this study, we demonstrate that loss of Pf1a dramatically accelerates invasive 
PDAC formation by removing an early, rate-limiting step to PanIN formation that is 
independent of canonical tumor suppressor gene regulation. Consistent with these findings, 
we show that sustained Ptf1a expression abolishes PanIN formation in vivo and limits 
acinar transformation in vitro. Our study additionally demonstrates the plasticity of pre-
cancerous cells, showing that they can be reprogrammed to a benign phenotype, despite 
harboring irreversible genetic lesions. 
Results 
Using a previously published RNA-seq dataset, we analyzed what cellular 
functions might be affected by Ptf1a deletion in adult acinar cells (Krah et al., 2015). The 
Ingenuity Pathway Analysis “Disease and Functions” tool revealed that deletion of Ptf1a, 
in the absence of oncogenic Kras, resulted in upregulation of gene expression modules 
relevant to cell migration, metastasis, cell invasion, and necrosis (Figure 5.1A). We 
therefore hypothesized that genetic deletion of Ptf1a may hasten development of invasive 
PDAC independently of canonical tumor suppressor genes such as Tp53. To test this 
hypothesis, we generated mice based on the well-characterized KPC (Kras, p53, Cre) 
pancreatic cancer model (Hingorani et al., 2005). In this system, an inducible, acinar 
specific Cre (Ptf1aCreERT) activates KrasG12D (expressed from the endogenous Kras locus 
(Tuveson et al., 2004)) and deletes both endogenous floxed p53 (Tp53) alleles following 
TM administration. Our experimental group contained these alleles, plus a “floxed” Ptf1a 
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allele, which we have utilized previously (Figure 5.2) (Krah et al., 2015). This allele 
combination allows us to determine if intact Ptf1a contributes to tumor suppression even 
when p53 is gone, i.e., independent of p53. To test whether Ptf1a deletion and p53 
deletion had distinct effects on pancreatic cancer initiation, we administered a single 
pulse of TM (0.25 mg/g body weight) to 6-8-week-old KPC and KPC; Ptf1a cKO mice 
and harvested pancreata after a 3-week chase (Figure 5.1B). In both experimental 
genotypes, total pancreas mass was not elevated above controls, suggesting that bona fide 
tumors had not yet formed in either genotype (Figure 5.1O). Histological examination 
revealed that KPC pancreata were nearly indistinguishable from controls at this early 
time point, exhibiting only rare PanIN lesions (Figure 5.1C-D). In contrast, the pancreata 
from KPC; Ptf1a cKO mice were composed exclusively of PanINs, ductal structures and 
fibroinflammatory infiltrate with little or no normal acinar tissue remaining (Figure 
5.1E). Alcian blue staining, which binds acidic mucins that are present in pancreatic 
PanINs but not normal ducts, confirmed that the PanIN burden in KPC; Ptf1a cKO was 
dramatically increased compared to KPC mice (Figure 5.1F-H, P). Given the severity of 
the pancreatic phenotype, however, surprisingly few of the abundant ductal lesions of 
KPC; Ptf1a cKO pancreata were organized into well-formed, Alcian blue-positive 
PanINs (Figure 5.1E, H). Instead, and in contrast to KPC pancreata, numerous 
disorganized clusters and sheets of CK19+ cells were found throughout KPC; Ptf1a cKO 
pancreata, resembling carcinoma in situ (Figure 5.1I-K). Sirius red staining revealed that 
the ubiquitous transformation in KPC; Ptf1a cKO pancreata was associated with a severe 
fibroinflammatory phenotype, suggesting that loss of acinar cell identity hastens the 
stromal reaction associated with PDAC (Figure 5.1L-N). These results demonstrate that 
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Ptf1a restrains PDAC initiation by limiting early transformation, independent of 
canonical tumor suppressor (p53, specifically) function. 
To test whether deletion of Ptf1a promotes progression to bona fide PDAC, we 
aged KPC and KPC; Ptf1a cKO mice that received a single pulse of TM (0.25 mg/g body 
weight) until they exhibited weight loss (20% of peak body weight), ascites, or lethargy. 
All ailing mice were found to harbor localized or metastatic pancreatic cancer. KPC; 
Ptf1a cKO mice had a median survival of 96 days, succumbing to PDAC much more 
rapidly than age-matched littermate KPC mice, which had a median survival of 160 days 
(Figure 5.3A). Interestingly, KPC; Ptf1a cKO were significantly more likely to be 
underweight at time of sacrifice (Figure 5.3B), perhaps due to longstanding exocrine 
insufficiency. However, primary tumors were indistinguishable between genotypes at the 
histological level and exhibited the classical features of PDAC, such as necrotic areas and 
CK19+ ductules (Figure 5.3C-D, G-H). Long-lived mice of both experimental genotypes 
exhibited liver and diaphragm metastases and ascites (Figure 5.3E-F and data not shown). 
Molecular characterization of primary tumors using mRNA-seq analysis revealed that 
very few genes were significantly differentially expressed between tumors from KPC and 
KPC; Ptf1a cKO mice (Red data points, Figure 5.3I). Interestingly, among the 30 genes 
significantly downregulated in KPC: Ptf1a cKO tumors were acinar-specific genes, such 
as amylase (Amy2b, Amy1), carboxypeptidase (Cpa2), and Chymotrypsin-C (Ctrc) 
(Figure 5.3I). Together, these data suggest that loss of Ptf1a does not alter the phenotype 
or invasive potential of pancreatic tumors, but rather hastens tumor progression by 
removing an early, rate-limiting barrier to tumor initiation.  
Given these results, we hypothesized that sustaining Ptf1a expression might be 
85 
able to inhibit PDAC initiation and progression. If correct, this hypothesis could lead to 
new therapeutic strategies for the disease, because unlike p53 and Kras, Ptf1a and its 
partner transcription factors are almost never genetically mutated in pancreatic cancer 
(Figure 5.4) (Bailey et al., 2016; Cerami et al., 2012; Gao et al., 2013). To test this 
hypothesis, we developed an acinar cell-specific, tamoxifen- and doxycycline (DOX)-
inducible mouse model that allows for independent control of KrasG12D and Ptf1a 
expression. In this model, TM administration activates KrasG12D and a reverse tetracycline 
transactivator protein (rtTA), which is constitutively expressed from the Rosa26 locus 
(Belteki et al., 2005; Collins et al., 2012a). Importantly, an IRES-GFP element placed 
downstream of the rtTA coding region allowed us to monitor the expression of this 
transgene using immunofluorescence. Subsequent administration of DOX drives rtTA-
dependent expression of a transgenic tetO-Ptf1a in as little as 24 hours, the expression of 
which can be monitored with a downstream IRES-LacZ element (Figure 5.5 and Figure 
5.6) (Willet et al., 2014).
To test whether sustained Ptf1a expression could inhibit the earliest phases of 
Kras-mediated PDAC development, we subjected control, KrasG12D and KrasG12D + tetO-
Ptf1a mice to high dose-TM and a subsequent 8-week chase during continuous 
administration of DOX (1 mg/mL in the drinking water) (Figure 5.7A). All mice 
harbored Ptf1aCreERT and Rosa26LSL-rtTA, and we confirmed that a similar percentage of acinar 
cells expressed rtTA-IRES-GFP between groups, indicating a uniform frequency of 
inducible Cre recombination (Figure 5.8).  After 8W, KrasG12 pancreata exhibited areas of 
edema (data not shown) and large areas of PanINs with associated fibroinflammatory 
infiltrate (Figure 5.7C). By contrast, PanINs were nearly absent in KrasG12D + tetO-Ptf1a 
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mice (Figure 5.7D). Regions of oncogenic transformation were highlighted by 
immunohistochemistry for the ductal gene CK19 (Figure 5.7E-G) and Alcian blue 
staining (Figure 5.7H-J). Quantifying the genotype-dependent PanIN burden revealed a 
drastic reduction in oncogenic transformation in KrasG12D + tetO-Ptf1a pancreata compared 
to those that expressed KrasG12D alone (Figure 5.7N, P<0.0001). 
To understand why a limited number of PanINs still formed in KrasG12D + tetO-
Ptf1a pancreata, we characterized these lesions relative to PanINs found in KrasG12D 
pancreata. There was no difference in the amount of Ki67 staining in the PanIN 
epithelium between genotypes (Figure 5.7K-M); lesions from both genotypes had various 
degrees of proliferation, indicating that they did not differ relating to this hallmark of 
cancer (Figure 5.7O). Interestingly, nearly all PanIN cells observed were completely 
negative for Ptf1a protein regardless of genotype, in contrast to adjacent acinar cells 
(Figure 5.7P-Q, V). These data indicate that there is not a unique population of PanINs 
that expresses transgenic Ptf1a in the KrasG12D + tetO-Ptf1a genotype, and suggests instead 
that cells comprising PanINs in this genotype are “escapers” that recombined the 
oncogenic Kras locus, but not the Rosa26 locus. Notably, a previous study found that the 
Rosa26LSL-rtTA allele was relatively resistant to Cre-mediated recombination, relative to other 
floxed alleles tested (Liu et al., 2013).  
To directly test whether PanINs arise from escaper cells in KrasG12D + tetO-Ptf1a 
mice, we quantified the number of PanINs that had individual cells coexpressing CK19 
and GFP (from Cre activation of rtTA-IRES-GFP). Most PanIN cells in KrasG12D pancreata 
co-expressed CK19 and GFP, indicating that they formed from acinar cells that had 
recombined both the KrasG12D and Rosa26 loci (Figure 5.7R, W). In contrast, almost all 
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PanIN cells in KrasG12D + tetO-Ptf1a pancreata were GFP-negative (Figure 5.7CS, W), 
indicating that they had not activated Rosa26LSL-rtTA. Thus, unequal Cre-mediated 
recombination between loci in a small population of acinar cells explains the residual 
formation of PanINs in KrasG12D + tetO-Ptf1a pancreata. We additionally confirmed that 
PanINs from KrasG12D + tetO-Ptf1a pancreata did not express tetO-Ptf1a by staining for 
LacZ. Indeed, PanINs harbored only very rare LacZ-positive cells, indicating that cells 
expressing Ptf1a-IRES-LacZ transgene were excluded from these precancerous lesions 
(Figure 5.7T-U). Taken together, these results strongly suggest that downregulation of 
Ptf1a expression is necessary for initiation of pancreatic cancer.  
 While screening tests for PDAC remain limited, risk factors have been identified 
in human epidemiology studies including chronic pancreatitis, obesity, and type 2 
diabetes (reviewed in Krah and Murtaugh, 2016). We therefore wanted to test whether 
sustaining Ptf1a expression in the context of a known pancreatic cancer risk factor would 
also inhibit cancer initiation. Since caerulein-induced pancreatitis is known to synergize 
with mutations in RAS to rapidly induce PanIN formation, we used this well-
characterized model to test our hypothesis (De La and Murtaugh, 2009; di Magliano and 
Logsdon, 2013; Guerra et al., 2007; Morris et al., 2010). Control, KrasG12D and KrasG12D + 
tetO-Ptf1a mice were administered high dose TM five days prior to caerulein treatment, 
and pancreata were harvested at three weeks after the final caerulein injection (Figure 
5.9A). In all groups, 1 mg/mL of DOX was present in the drinking water throughout the 
experiment. While control mice completely recovered from caerulein-induced 
pancreatitis, robust PanIN formation was seen in the KrasG12D genotype, as expected (F 
Figure 5.9B-C). In contrast, KrasG12D + tetO-Ptf1a pancreata exhibited little PanIN 
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formation and lacked the large fibro-inflammatory regions characteristic of caerulein-
treated KrasG12D mice (Figure 5.9D). To highlight PanIN burden, we performed 
immunohistochemistry for CK19 and stained with Alcian blue, which confirmed a 
dramatic reduction in PanINs in KrasG12D + tetO-Ptf1a mice (Figure 5.9E-J, Q). As in our 
previous experiment, PanINs in KrasG12D + tetO-Ptf1a were almost completely Ptf1a-
negative (Figure 5.9K-M) and were comprised almost exclusively of escaper cells (Figure 
5.9N-P, R). Thus, even in a robust model of PDAC initiation that mimics a well-
characterized human risk factor (Lowenfels et al., 1993), sustained Ptf1a expression is 
sufficient to limit disease initiation. 
 As pancreatitis involves the complex interaction between the stromal 
microenvironment and epithelial acinar cells, we next wanted to determine whether Ptf1a 
could restrain transformation in the absence of extrinsic inputs. To do this, we utilized a 
3-dimensional (3D) culture system in which clusters of acinar cells undergo metaplasia
into ductal cysts in response to mutant Kras signaling, without stimuli from the stromal 
microenvironment (Ardito et al., 2012; Krah et al., 2015; Means et al., 2005). Acinar 
clusters were isolated from KrasG12D and KrasG12D + tetO-Ptf1a mice, not treated with DOX, 
8-weeks after the final TM dose and embedded in a collagen matrix, as previously
described (n=4 mice) (Ardito et al., 2012; Means et al., 2005). In initial experiments, we 
treated acinar cluster with vehicle alone or DOX from the time they were plated and 
measured the number of transformed clusters and the area of transformed cysts at 3 and 5 
days after plating. At day 3, significantly fewer DOX-treated acinar clusters had 
transformed into ductal cysts (Figure 5.10A-C), and those that had transformed were 
significantly smaller, as measured by cyst area (Figure 5.10D). Five days after treatment, 
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however, most acinar clusters had undergone some degree of transformation regardless of 
treatment (Figure 5.10E-G). DOX-treated cysts remained significantly smaller (Figure 
5.10H) measured by cyst area, suggesting that sustained Ptf1a expression delays acinar 
transformation and restrains cyst expansion in this ex vivo system.  
 The therapeutic potential of these findings would be most impactful if 
reintroduction of Ptf1a into established lesions could redirect their fate to healthy acinar 
tissue, induce cell death, or inhibit further progression toward invasiveness. To begin to 
test whether re-expression of Ptf1a could halt transformation, we allowed untreated cysts 
from KrasG12D + tetO-Ptf1a pancreata to form in our 3D acinar culture system for three 
days and then treated with vehicle or DOX (Figure 5.10I). While cysts treated with 
vehicle increased in area from day three to five, those treated with DOX remained the 
same size, suggesting that reintroduction of Ptf1a can stop the progression of cysts in this 
system (Figure 5.10J-N). Taken together, these data suggest that the induction of Ptf1a 
inhibits initial metaplasia and the progression of established transformed cells.  
 We therefore sought to utilize our KrasG12D + tetO-Ptf1a mouse model to examine 
whether reintroduction of Ptf1a into PanINs would have a similar effect in vivo. As 
PanINs in KrasG12D + tetO-Ptf1a on DOX were comprised exclusively of rtTA-negative 
cells (Figure 5.7S), we first wanted to confirm that these mice form RosartTA-GFP-positive 
PanINs when administered TM, but not DOX. Indeed, 8-weeks after TM administration, 
DOX-untreated KrasG12D + tetO-Ptf1a mice exhibited widespread CK19/GFP dual-positive 
PanINs, confirming that these lesions express the cellular machinery necessary to re-
express transgenic tetO-Ptf1a (Figure 5.11A). To test whether transformed PanINs could 
express the tetO-Ptf1a transgene, we administered KrasG12D + tetO-Ptf1a TM on three 
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consecutive days and allowed PanINs to form during an 8-week chase. These mice then 
either remained on normal drinking water or received DOX in their drinking water for 24 
hours before we harvested pancreata. While mice that did not receive DOX (or did not 
have the tetO-Ptf1a transgene) had no LacZ-positive cells anywhere in their pancreata, 
we observed normal acinar cells and several PanINs that were robustly LacZ-positive in 
the 24h DOX treated group (Figure 5.11D and data not shown). These results confirm 
that tetO-Ptf1a can be expressed in PanINs using our TM and DOX inducible model. 
 To determine the effect of Ptf1a re-expression in PanINs, KrasG12D + tetO-Ptf1a 
received three pulses of TM on consecutive days before an 8-week chase without DOX. 
Once PanINs had formed at 8 weeks, we administered 1 mg/mL DOX in the drinking 
water for 3 or six 6 before sacrifice. Three weeks after induction with DOX, we observed 
misplaced acinar cells interspersed within PanIN lesions throughout KrasG12D + tetO-Ptf1a 
pancreata, which were noticeably absent from KrasG12D mice that underwent the same 
protocol (Figure 5.12A-B). Pancreata from KrasG12D + tetO-Ptf1a mice were 
heterogeneous, exhibiting what appear to be wide-spread resolving PanINs and ductules 
at this time-point, and consistent with this observation, Alcian blue staining revealed 
numerous small, dissolving PanINs, intermixed with misplaced acinar cells (Figure 
5.12C-D). To determine whether these misplaced acinar cells were expressing tetO-Ptf1a, 
we performed immunohistochemistry for Ptf1a (Figure 5.12E-F) and 
immunofluorescence for rtTA-GFP, amylase, and Ck19 (Figure 5.11A-C). Indeed, 3 
weeks after DOX treatment, there was a significant increase in the number of hybrid 
acinar-duct structures, which had the histological appearance of embryonic acinar cells 
emerging from CK19-positive PanINs (Figure 5.11B, H). Consistent with these being 
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cells that reexpressed Ptf1a (Figure 5.11B), these clusters were almost ubiquitously 
LacZ-positive, indicating that they express tetO-Ptf1a (Figure 5.11E).  
 To confirm that redifferentiating GFP+ cells were emerging out of PanINs (and 
not being recruited into them), we quantified the number of CK19/GFP dual positive 
lesions in the following groups: 8-weeks NO DOX treatment, 8-weeks OFF DOX + 3-
weeks ON DOX, and 8-weeks OFF DOX + 6-weeks ON DOX. While KrasG12D + tetO-
Ptf1a mice that were not treated with DOX had ~70% CK19/GFP dual positive PanINs, 
KrasG12D + tetO- treated subsequently with DOX for 3-weeks or 6-weeks had dramatically 
fewer (26% and 9%, respectively) GFP+ cells contributing to PanINs (Figure 5.11B-C, 
G), suggesting that these cells had lost their oncogenic potential. LacZ staining confirmed 
that there were few, if any, tetO-Ptf1a-expressing cells contributing to PanINs after 6 
weeks with DOX treatment (Figure 5.11F). Taken together, these data suggest that Ptf1a-
expressing cells cannot maintain a preoncogenic phenotype, and demonstrate that PDAC 
precursors can be reprogrammed to a benign phenotype, despite harboring irreversible 
cancer-driving mutations. 
Discussion 
 Acinar-to-ductal reprogramming has become a widely-appreciated step in the 
genesis of pre-cancerous PanINs (De La et al., 2008; Habbe et al., 2008; Kopp et al., 
2012; Merrell and Stanger, 2016). Several recent studies suggest that acinar 
differentiation determinants, such as Ptf1a and Nr5a2, are required to prevent acinar 
metaplasia, even under homeostatic conditions (Hoang et al., 2016; Holmstrom et al., 
2011; Krah et al., 2015; von Figura et al., 2014). Indeed, genetic deletion of these 
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transcription factors allows for oncogenic Kras to rapidly reprogram acinar cells into 
PanINs, suggesting that alterations in cell fate are a rate-limiting step in PDAC initiation 
(Flandez et al., 2014; Krah et al., 2015; Shi et al., 2009; von Figura et al., 2014). Here, we 
show that this rate-limiting step toward PanIN development also accelerates the 
formation of carcinoma in situ and invasive cancer when p53 is simultaneously deleted 
(Figures 5.1 and 5.3). Additionally, we demonstrate that loss of Ptf1a is necessary for the 
earliest steps of oncogenic reprogramming, as the maintenance or re-introduction of Ptf1a 
expression prevents acinar transformation and limits oncogenic potential. 
 The potent combination of KrasG12D activation with deletion of Ptf1a and p53 was 
sufficient to generate carcinoma in situ within 3 weeks of Cre-mediated recombination 
(Figure 5.1). This rapid time-scale to potential invasiveness is consistent with the cellular 
functions that Ptf1a is projected to restrain, but surprising given that pancreata from KPC 
mice remain relatively normal, with only sparse, well-organized PanINs at this early 
time-point. The contrast between the indolence of KPC epithelial cells, 3 weeks after 
tamoxifen administration, and the invasive phenotype of KPC; Ptf1a cKO epithelial at 
this time point suggests that the presence of Ptf1a is able to inhibit tumor formation even 
after cells have already sustained genetic “hits” typical of advanced PanINs and PDAC 
(Hosoda et al., 2017). With Ptf1a removed, cells with KrasG12D and no p53 are disinhibited 
and rapidly progress to carcinoma (Figure 5.3A). Our data therefore highlight the 
importance of cell differentiation, which can restrain transformation of cells with 
irreversible genetic lesions for months.  
 Of note, several recent studies demonstrate that other pancreatic differentiation 
determinants, such as Nr5a2 and Pdx1, restrain acinar cell transformation in the presence 
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of oncogenic Kras. For example, the Crawford and Hebrok labs recently demonstrated 
that deletion of Pdx1 dramatically hastens PanIN formation, when on a KrasG12D 
background (Roy et al., 2016). Similarly, Nr5a2, which coordinates acinar-specific gene 
expression with Ptf1a (Holmstrom et al., 2011),  greatly accelerates PanIN formation 
when even a single allele is deleted (Flandez et al., 2014; von Figura et al., 2014). 
Consistent with these findings in mouse, GWAS studies have shown that SNPs in NR5A2 
increase the risk of human PDAC development (Li et al., 2012; Petersen et al., 2010), 
highlighting the relevance of acinar differentiation to human tumors. Additionally, forced 
expression of the Ptf1a binding partner, E47, in PDAC cells in vitro prevents cell 
proliferation and induces the expression of acinar-specific genes, demonstrating the 
plasticity of invasive PDAC cells (Kim et al., 2015). Going forward it will be interesting 
to test whether simultaneous activation of Ptf1a, Nr5a2 and E47 in PanINs or PDAC cells 
leads to a more robust reprogramming effect.  
 To our knowledge, this is one of the first studies demonstrating plasticity in vivo 
of tumor precursor cells. Previous work from the Pasca di Magliano lab has shown that 
inhibiting KrasG12D directly, using a similar DOX inducible system to what we utilize in 
this study, leads to the regression of PanINs and PDAC (Collins et al., 2012a; Collins et 
al., 2012b). However, targeting oncogenic RAS in solid tumors has proven to be a 
monumental challenge (Collins and Pasca di Magliano, 2013; McCormick, 2015). 
Previous studies from our lab suggest that loss of Ptf1a alone upregulates genes 
associated with RAS dependency in human cancer cells (Krah et al., 2015). Restoring 
Ptf1a expression may therefore provide inhibitory effect on RAS signaling in PanINs or 
tumor cells, bypassing the need to directly restrain mutant Kras. The fact that acinar 
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differentiation can restrain transformation of cells with oncogenic Kras and loss of p53 
for months in the KPC model, and reverse the phenotype of PanINs, speaks to the power 
of this transcriptional network in inhibiting tumor initiation. Future studies should aim to 
understand the mechanisms by which Ptf1a and other components of its regulatory 
networked are silenced in PanINs and PDAC to devise strategies for their reactivation. 
Similar concepts may apply to other insidious solid cancers, such as hepatocellular 
carcinoma and colorectal cancer, where cellular plasticity is well-documented and the 
transcriptional programs that define mature cell types are well characterized (Krah and 
Murtaugh, 2016).  
Materials and Methods 
Mice 
 Experimental mice of the following genotypes have been utilized in previous 
publications: Ptf1aCreERT (Ptf1atm2(CreER1)CVW) (Kopinke et al., 2012; Krah et al., 2015), KrasLSL-G12D 
(Krastm4tyj) (Hingorani et al., 2003), p53lox (Trp53tm1Bm) (Marino et al., 2000), Ptf1alox (Ptf1atm3Cvw) 
(Hoang et al., 2016; Krah et al., 2015), RosartTA (Belteki et al., 2005; Collins et al., 2012a; 
Collins et al., 2012b), and tetO-Ptf1a (Willet et al., 2014). To induce Cre-mediated 
recombination, mice were administered tamoxifen (Sigma, St. Louis, MO) dissolved in 
corn oil, via oral gavage, at doses indicated within the text. All experiments involving 
mice were performed according to institutional and National Institutes of Health (NIH) 
guidelines.  
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Tissue processing and histology
 Following euthanasia, pancreata were dissected into ice cold PBS and separated 
into multiple parts and processed for frozen and paraffin sections, as previously described 
by our lab (De La et al., 2008; Keefe et al., 2012). For paraffin sectioning, tissues were 
fixed in zinc-buffered formalin (Z-fix; Anatech, Battle Creek, MI) at room temperature 
overnight, followed by processing into Paraplast plus (McCormick Scientific). Frozen 
histological specimens were fixed for 1-2 hours in 4% paraformaldehyde in 1x PBS on 
ice, followed by processing into Tissue-Tek O.C.T. compound (Sakua Fineteck, 
Torrance, CA). Both paraffin and frozen sections were cut at a thickness of 6-8µm with 
over 100µm spacing between individual sections on a single slide.  
 Immunohistochemistry and immunofluorescence followed established protocols 
from our lab (De La et al., 2008; Keefe et al., 2012; Krah et al., 2015) and included high 
temperature antigen retrieval (Vector Unmasking Solution; Vector Laboratories, 
Burlingame, CA), prior to staining all paraffin sections. All primary antibodies have been 
previously utilized by our lab (see Table 3.2). Secondary antibodies, raised in donkey
(Jackson Immunoresearch, West Grove, PA) were used at a dilution of 1:250 in blocking 
solution. Vectastain reagents and diaminobenzidine (DAB) substrate (Vector 
Laboratories) were used for all IHC experiments. Immunofluorescence were 
counterstained with DAPI and mounted in Fluoromount-G (Southern Biotech), and 
photographed on an Olympus IX71 microscope, using MicroSuite software (Olympus 
America, Waltham, MA). Images were processed in Adobe Photoshop, with exposure 
times and adjustments identical between genotypes and treatment groups.  
Alcian blue staining was performed on paraffin sections following a 15-min wash 
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in 3% acetic acid, followed by a 10-min incubation in staining solution (1% Alcian blue 
in 3% acetic acid), followed by extensive washes in 3% acetic acid and 1x PBS. Sirius 
red staining was performed on frozen sections that were fixed in Bouin’s fixative at 55˚C 
for 1 hour. Specimens were washed in dH2O and stained for 1 hour in Picro-Sirius Red 
(American MasterTech, Lodi, CA). Following staining, all slides were washed in 0.5% 
acetic acid, dehydrated and equilibrated into xylene, and mounted with Permount.  
PanIN scoring 
 To measure the number of PanINs in each pancreas, the entire tissue area of 
Alcian blue/eosin-stained specimen was photographed at 4x original magnification, 
followed by Photomerging (Adobe Photoshop). The surface area was measured using 
ImageJ software (NIH). Alcian blue+ PanINs were counted manually under the 
microscope and PanIN burden was calculated as the total number of Alcian blue+ lesions 
per cm2 surface area. As previously described, metaplastic lesions that did not stain with 
Alcian blue were not counted in the quantification. To avoid double-counting tortuous 
lesions that could occupy multiple regions in three-dimensional space, no more than one 
lesion was scored within an anatomically distinct pancreatic lobule (De La et al., 2008; 
Krah et al., 2015).  
RNA-sequencing analysis 
 Tumors from KPC and KPC; Ptf1a cKO mice were homogenized and total RNA 
was isolated using a modified guanidine thiocyanate-guanidine hydrochloride extraction 
(Hoang et al., 2016; Krah et al., 2015). After the first precipitation, the RNA was 
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dissolved in equal parts of Trizol and purified using the Direct-zol RNA (Zymo) 
according to the manufacturer’s instructions. RNA quality was accessed by Agilent 
Bioanalyzer with KPC mice having an average RIN value of 8.5 and KPC+P an average 
value of 9. Poly-A selection and the Illumina TruSeq Stranded mRNA Library 
Preparation Kit were used to generate libraries. Fifty cycles of single-read sequencing 
were conducted using the Illumina HiSeq 2500 instrument. Reads were aligned to UCSC 
mm10 genome by Tophat (v2.1.1) and EdgeR default settings were used to determine 
differential expression of genes (FDR <0.05). 
Caerulein treatment
 Acute pancreatitis was induced by i.p. injection of caerulein (Bachem, Torrance, 
CA), 0.1 ug/g in saline, six times daily over two consecutive days, as previously 
described (Keefe et al., 2012; Kopp et al., 2012; Krah et al., 2015). Negative controls 
were injected with an equal volume of saline. Pancreata from all caerulein-treated mice 
were harvested three weeks following the final injection and processed as described 
above.  
Kaplan-Meier analysis
 KPC mice (genotype: Ptf1aCreERT/+; KrasG12D; p53lox/lox) and KPC; Ptf1a cKO mice 
(genotype: Ptf1aCreERT/lox; KrasG12D; p53lox/lox) were aged until they exhibited lethargy, distress, 
>20% weight loss of peak body weight, or ascites, as determined by NMK or the in house
veterinary staff. The presence of PDAC and metastases was confirmed by histological 
analysis in consultation with a surgical pathologist. Survival analysis was performed in 
98 
GraphPad Prism 7 and p-values were calculated using a Log-rank test and Gehan-
Breslow-Wilcoxon test.  
3D pancreatic acinar cultures 
 Acinar cultures were established following protocols from previous publications 
(Ardito et al., 2012; Means et al., 2005). Briefly, the dorsal pancreas was minced in 
HBSS and digested in 0.02% trypsin (5 min, 37˚C) and 1 mg/mL collagenase P (Roche 
Applied Science, Mannheim, Germany; 15 min, 37˚C). the resulting digest was filtered to 
eliminate undigested material and repeated washing was performed to eliminate debris 
and dead cells. Acinar cell clusters were embedded in rat tail collagen gels (Corning, 
Corning, NY) and cultured in Weymouth’s medium (Life Technologies, Carlsbad, CA) 
supplemented with 1% fetal bovine serum, 0.4 mg/mL soybean trypsin inhibitor, and 1 
µg/mL dexamethasone. Cultures were fixed and imaged 3 or 5 days after plating. To 
quantify cyst size, we randomly selected >12 fields per mouse, imaged and quantified the 
area of each transformed cyst using imageJ (NIH).  
Quantification of immunofluorescence images 
 To quantify the Rosa26rtTA recombination frequency, we imaged 10-12 randomly 
selected 20x fields per specimen (taken across multiple sections). Using ImageJ (NIH), 
cell coexpressing GFP with the acinar differentiation marker, Amylase, were detected by 
additive image overlay of their staining with DAPI and anti-GFP, and counted using the 
Analyze Particles function as described previously (Keefe et al., 2012; Kopinke et al., 
2012). To ensure counting accuracy, random images were manually spot-checked, using 
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Adobe Photoshop. All calculations were performed in Microsoft Excel and the results are 
graphed as individuals with error bars representing the standard deviation. P-values were 
determined by a two-tailed, unpaired t-test in Graphpad Prism 7.  
 To quantify the number of GFP-positive PanINs, 10 randomly selected field were 
imaged per mouse. Each PanIN was hand scored according to the number of GFP and 
CK19+ cells over-lay with one another. If more than two cells co-expressed CK19 and 
GFP, the PanIN was considered GFP-positive.  
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Figure 5.1. Loss of Ptf1a leads to rapid progression toward PDAC in KPC mice, 
independently of p53 loss. (A) Heat map of disease and functions from ingenuity 
pathway analysis predicted from the changes in gene expression in Ptf1a cKO pancreata. 
Analyses are based on a +/- expression threshold of 2.0. (B) Schematic of experimental 
design: mice of specified genotypes were administered a single pulse of 0.25 mg/g body 
weight TM to induce Cre-mediated recombination and were sacrificed three weeks later. 
(C-E) H&E staining of pancreata from mice of indicated genotypes three weeks after TM 
gavage. (F-H) Alcian blue staining, which highlights PanIN formation in KPC + Ptf1a 
cKO pancreata. (I-K) IHC for the ductal gene marker Cytokeratin-19 (CK19), 
highlighting normal ducts in control pancreata, well organized, oval PanINs in KPC 
mice, and sheets of disorganized epithelial cells in KPC + Ptf1a cKO pancreata. (L-N) 
Sirius Red staining, highlighting wide-spread fibrosis in KPC + Ptf1a cKO pancreata. 
(O) Pancreas mass, measured as a percent of body weight, was not significantly different 
between genotypes at 3W post TM administration. (P) Quantification of PanINs at 3-
weeks post TM. KPC + Ptf1a cKO pancreata exhibited a 5-fold increase in Alcian Blue+ 
PanINs compared to KPC pancreata at this time-point (P<0.001).  
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Figure 5.2. Schematic of mouse alleles used in Figures 5.1 and 5.3. Schematic 
representations of the alleles present in the genotypes referred to, in shorthand, as 
Control, KPC, and KPC; Ptf1a cKO. 
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Figure 5.3. Loss of Ptf1a accelerates progression to PDAC, but does not drastically 
alter tumor phenotype. (A) Kaplan-Meier analysis from KPC mice (Ptf1aCreERT/+; KrasG12D; 
p53lox/lox, blue line) and age-matched KPC; Ptf1a cKO (Ptf1aCreERT/lox; KrasG12D; p53lox/lox, red line) 
mice that received TM at 6W of age (Log rank test: P<0.01). (B) Mass of male and 
female KPC and KPC; Ptf1a cKO mice at the time of sacrifice. Representative H&E 
stained histology from primary tumors (C-D) and liver metastases (E-F) from mice of 
indicated genotypes. (G-H) IHC for CK19, highlighting tumor epithelium in primary 
tumors from mice of indicated genotypes. (I) Volcano plot showing expressed genes in 
KPC and KPC; Ptf1a cKO tumors (Black dots). Grey data points represent genes that 
have a fold change >2.0 but do not reach statistical significance. Red dots are genes that 
have an FDR<0.05 and are differentially expressed. Downregulated acinar specific genes 
with FDR<0.05 are highlighted as blue dots and labeled with the gene name (Amy1, 
Amy2b, Cpa2, and Ctrc).  
 108 
Figure 5.4. Common and uncommon mutations in human PDAC. Mutational profile 
of common driver mutations, KRAS and TP53, and uncommonly mutated genes such as, 
NR5A2, PTF1A, RBPJL, GATA4, and SOX9. Each gray bar represents an individual case. 
Green bars represent cases with a missense mutation in the indicated gene, while black 










Figure 5.5. A mouse model to induce and sustain Ptf1a expression in acinar cells. (A) 
Experimental schematic to induce sustained Ptf1a expression using alleles described 
below (B-D). Prior to tamoxifen (TM) administration, Cre is expressed from the 
endogenous Ptf1a locus, but is sequestered to the cytoplasm (B). When TM is 
administered the Rosa26 locus undergoes Cre-mediated recombination, which drives the 
constitutive expression of a reverse tetracycline transactivation element (rtTA) (C). Since 
rtTA is conjugated to an IRES-GFP, the cells that recombine this locus permanently 
express GFP. (D) Upon administration of DOX, the rtTA can enter the nucleus and drive 
constitutive expression of the tetO-Ptf1a transgene; cells that express tetO-Ptf1a can be 
monitored with LacZ expression. (E-F) Gross pancreata of indicated genotypes 24h 
following DOX administration. (G-H) Histology of pancreata represented in E-F, which 
highlights the LacZ expression specific to acinar cells. (I-J) 72 hours following DOX 
administration, similar acinar specific LacZ expression, which does not alter the 





Figure 5.6. Mouse alleles utilized in Figures 5.7 through 5.12. Schematic 
representations of the alleles present in the genotypes referred to, in shorthand, as 
Control, KrasG12D, and KrasG12D + tetO-Ptf1a. Function of the system is described in Figure 
5.5.  
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Figure 5.7 Sustained Ptf1a expression prevents KrasG12D-driven PanIN formation. (A) 
Mice of indicated genotypes were administered 1 mg/mL DOX in their drinking water 24 
hours before being gavaged with 0.25 mg/g body weight TM on three consecutive days to 
induce Cre-mediated recombination. 8W following the final TM gavage, mice were 
sacrificed for pancreatic histology. (B-D) H&E staining of pancreata from mice of 
indicated genotypes 8W after TM administration. IHC for CK19 (E-G) and alcian blue 
staining (H-J), highlighting the reduced PanIN burden in in KrasG12D; tetO-Ptf1a pancreata 
compared to those that express KrasG12D only. (K-M) IHC for Ki67, specifically in PanINs 
of mice of indicated genotypes. (N) Quantification of the genotype dependent PanIN 
burden, showing a drastic reduction in the number of alcian blue+ lesions in KrasG12D; 
tetO-Ptf1a pancreata compared to KrasG12D pancreata (P<0.001). (O) Quantification of 
graded PanINs for proliferation based on Ki67 staining; there was no statistically 
significant difference between genotypes. (P-Q) IHC for Ptf1a, showing the lack of 
nuclear Ptf1a in PanINs, compared to adjacent acinar cells in both genotypes. (R-S) 
Immunofluorescence for the duct marker CK19 (red), the RosartTA-GFP acinar lineage label 
(green), and dapi (blue). (T-U) Staining for CK19, the tetO-Ptf1a-IRES-LacZ and nuclear 
fast red. (V) Quantification of the number of PanINs that are completely Ptf1a negative 
vs. those that harbor 1 or more Ptf1a positive cells (n.s. = no significance between 
genotypes). (W) Quantification of the number of PanINs that are only CK19 positive vs. 
those that are CK19/ RosartTA-GFP dual positive (Fisher exact test, P<0.01).  
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Figure 5.8: Ptf1aCreERT recombination efficiency following tamoxifen treatment. (A) 6-
8-week-old mice were administered tamoxifen on three consecutive days (3 x 0.25 mg/g
mouse) while DOX (1 mg/mL) was present in the drinking water, and pancreata were
harvested after an 8-week chase. (B-D) Immunofluorescence for amylase (red) and the
Cre reporter Rosa26rtTA-GFP (green) on pancreata from mice of indicated genotypes. For all
mice, only histologically normal areas were imaged in an effort to provide an accurate
quantification of Cre-mediated recombination. (E) The proportion of GFP expression
among amylase+ acinar cells were quantified for KrasG12D, and KrasG12D + tetO-Ptf1a
genotypes. No significant difference was noted between any individuals or genotype
groups.
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Figure 5.9. Maintenance of acinar identity inhibits Kras-driven PanIN formation 
during pancreatitis. (A) Experimental design: mice were first administered 1mg/mL 
DOX in their drinking water before receiving one dose of 0.25 mg/g Tamoxifen on three 
consecutive days. Five days following the final TM dose, mice were administered six 
hourly injections of 0.1µg/g caerulein on two consecutive days. Three weeks following 
the final caerulein injection, mice were sacrificed to analyze pancreatic histology. (B-D) 
H&E staining of pancreata from mice of indicated genotypes 3W after caerulein-induced 
pancreatitis. IHC for CK19 (E-G) and alcian blue staining (H-J) highlighting PanIN 
burden. (K-M) IHC for Ptf1a, showing the lack of nuclear Ptf1a in normal ducts in 
control mice (K), and in PanINs (L-M), compared to adjacent acinar cells. (N-P) 
Immunofluorescence for the duct marker CK19 (red), the RosartTA-GFP acinar lineage label 
(green), and dapi (blue), highlighting CK19+ escaper PanIN cells in KrasG12D; tetO-Ptf1a 
pancreata (P). (Q) Quantification of the genotype dependent PanIN burden, showing a 
drastic reduction in the number of PanINs in KrasG12D; tetO-Ptf1a pancreata (P<0.01). (R) 
Quantification of number of PanINs that are only CK19 positive vs. those that are CK19/ 









Figure 5.10. Ptf1a limits acinar-to-ductal reprogramming and inhibits ductal 
expansion in 3D culture. (A-B) Brightfield images of transforming acinar cluster from 
KrasG12D; tetO-Ptf1a pancreata in the presence or absence of DOX three days after plating. 
(C and G) Quantification of the proportion of transformed clusters in the absence and 
presence of DOX either three (C) or five (G) days after plating (Fisher exact test, 
P<0.001). (D, H) Quantification of ductal area of transformed cysts 3 or 5 days after 
plating in the presence and absence of DOX. Each data point represents a single 
quantified sphere from one of four biological replicates (t-test, P<0.001). (E-F) 
Brightfield images acinar-derived ductal cysts from KrasG12D; tetO-Ptf1a pancreata in the 
presence or absence of DOX five days after plating. Metaplastic ductules were allowed to 
form for three days before DOX or vehicle was added (I). (J,L) Brightfield images of 
untreated transformed ducts at day 3, before the addition of DOX or vehicle. (K,M) 
Brightfield images of metaplastic ducts after 2 days of treatment with DOX or vehicle. 
(N) Quantification of duct area at day 3, prior to treatment, and day 5, after DOX/vehicle 









Figure 5.11. Re-expression of Ptf1a in PanINs leads to the emergence of primitive 
acinar cells. (A-C) Immunofluorescence for the duct marker CK19 (red), the RosartTA-GFP 
acinar lineage label (green), and dapi (blue) demonstrating GFP+ PanINs in KrasG12D; tetO-
Ptf1a pancreata with only 24h DOX treatment (A) and highlighting largely GFP-negative 
PanINs in KrasG12D; tetO-Ptf1a pancreata after 3 weeks or 6 weeks with DOX treatment 
(B-C). (B’) The blow-up image highlights GFP+ primitive acinar cells emerging from a 
CK19+ lesion. (D-F) Staining for CK19, the tetO-Ptf1a-IRES-LacZ and nuclear fast red 
in mice of indicated genotypes and treatments. 24 hours of DOX treatment in mice with 
pre-formed PanINs is sufficient to drive tetO-Ptf1a expression in PanINs (D). (E-F) 
Staining for CK19, the tetO-Ptf1a-IRES-LacZ and nuclear fast red, highlighting clusters 
of LacZ-positive emerging from CK19+ lesions (E’) and LacZ-negative PanINs 6 weeks 
after treatment (F).   
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Figure 5.12. Re-expression of Ptf1a  reduces PanIN burden in KrasG12D + tetO-Ptf1a 
pancreata. H&E (A-B) and Alcian blue (C-D) staining of pancreata from mice of 
indicated genotypes and treatments. (B) Highlights primitive acinar cells trapped within 
PanIN lesions. (E-F) Immunohistochemistry for Ptf1a, showing absence of Ptf1a in 
PanINs from KrasG12D pancreata and wide Ptf1a expression in duct-like structures in 
KrasG12D + tetO-Ptf1a pancreata. (G) Quantification of genotype dependent PanIN burden 
following the treatment regimen 8 weeks without DOX, 3 weeks with DOX treatment. 
P<0.05.  




CONCLUSIONS AND FUTURE DIRECTIONS 
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While pancreatic ductal adenocarcinoma (PDAC) remains one of the worst 
diseases in medicine, the last 10 years have seen remarkable developments in 
understanding the molecular origins of disease. Genetically engineered mouse models 
(GEMMs) have provided great insight into both the cell of origin and the pathways 
required to initiate PDAC. Mirroring what is seen in human disease, GEMMs of PDAC 
develop precancerous pancreatic intraepithelial neoplasia (PanINs), which can become 
invasive following tumor suppressor mutation or deletion (Aguirre et al., 2003; Bardeesy 
et al., 2006; Hingorani et al., 2003; Hingorani et al., 2005; Hruban et al., 2000). Notably, 
the classic progression model of PanIN-to-PDAC involves the increasing influence of 
non-cell-autonomous effects, such as desmoplasia and immune-epithelial cross-talk, 
which go on to make the fibrotic stroma associated with invasive tumors (di Magliano 
and Logsdon, 2013; Hruban et al., 2000; Morris et al., 2010b). 
Although the duct-like phenotype of PanINs and the epithelial cells in PDAC 
tumors might suggest that the disease originates from duct cells, our lab and others have 
shown that acinar cells are much more susceptible to Kras-mediated oncogenic 
transformation than ducts (Bailey et al., 2015; De La et al., 2008; Habbe et al., 2008; Ji et 
al., 2009; Kopp et al., 2012; Ray et al., 2011). Evidence strongly suggests that PDAC is 
initiated by a metaplastic step in which acinar cells downregulate transcription factors 
that maintain cell identity, usually in response to KrasG12D mutation or pancreatic 
inflammation (De La et al., 2008; De La and Murtaugh, 2009; Guerra et al., 2007) 
(Figure 6.1). This intermediate, metaplastic cell type is uniquely sensitive to oncogenic 
transformation and PanIN formation. We therefore hypothesized that forced loss of acinar 
cell differentiation, via genetic Ptf1a deletion, could be a rate-limiting step for PDAC 
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initiation. In my dissertation, I demonstrate that Ptf1a maintains acinar cell homeostasis 
and limits metaplasia; in the presence of oncogenic Kras, Ptf1a limits the formation of 
precancerous pancreatic intraepithelial neoplasia (PanIN), and subsequent PDAC 
formation (Chapter 3). Acinar differentiation determinants, such as Ptf1a and Nr5a2, are 
also required for acinar cell regeneration following acute pancreatitis (Krah et al., 2015; 
von Figura et al., 2014). Perhaps most strikingly, my unpublished results indicate that 
maintaining acinar differentiation, via sustained or reintroduced Ptf1a expression, inhibits 
PanIN initiation (Chapter 5) (Figure 6.1).  
The conventional PanIN-to-PDAC progression model depicts PanINs as 
intermediate stages in the progression to cancer, yet early-stage PanINs are almost found 
in more than half of randomly-selected healthy pancreata, despite a lifetime PDAC risk of 
only ~1% (Andea et al., 2003; Rebours et al., 2015). Consistent with an inherent low risk 
of progression, PanINs formed in the KC (KrasG12D, Cre) mouse model, or our inducible 
KrasG12D; Ptf1a cKO mouse (Chapter 3), rarely give rise to invasive carcinoma in the 
absence of engineered p53 mutation/deletion, even when aged for 9-12 months 
(Hingorani et al., 2003; Hingorani et al., 2005; Krah et al., 2015). This observation is 
particularly striking in long-aged KrasG12D; Ptf1a cKO mice where the entire pancreas is 
comprised of intermediate-grade PanINs for several months (Krah et al., 2015). These 
observations raise the possibility that PanINs could act in a host-protective manner, by 
isolating potentially oncogenic cells and denying them the ability to invade and 
metastasize (see Chapter 2). This idea is supported by the heterogeneity of these 
precancerous lesions; in humans, most cells comprising low-grade PanINs do not harbor 
Kras mutations, suggesting that PanINs emerge from multiple nonmutant cells and 
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remain polyclonal (Kanda et al., 2012). In contrast, in acinar-KrasG12D mice, lineage 
tracing reveals that reprogrammed acinar ductules can be polyclonal, but PanIN-1 lesions 
are almost exclusively monoclonal (Maddipati and Stanger, 2015).  
Due to a lack of appropriate molecular tools, however, it remains unclear whether 
wild-type acinar cells contribute to PanINs during PanIN formation in mice. To address 
this, our lab is currently engineering a KrasG12D-EGFP allele, in which EGFP will be 
inserted upstream of endogenously expressed KrasG12D allele and coexpressed via a viral 
T2A peptide (Murtaugh lab, unpublished). This allele will allow us to directly observe 
the phenotype of Kras-mutant and Kras-wild-type cells. With current methodology, Cre 
must recombine the Kras allele and the Rosa26 allele, where reporter constructs are often 
placed for lineage tracing.  This creates the opportunity for unequal Cre-mediated 
recombination, where one allele is activated, but the other is not (Liu et al., 2013). As we 
describe in Chapter 5, this unequal recombination leads to many Kras-mutant cells that 
do not express a lineage label (and vice-versa). However, the KrasG12D-EGFP mouse will 
allow us to directly test whether PanINs contain a mix of KrasG12D-positive and normal 
cells.  
If wild-type acinar cells are reprogrammed to capture a sparse Kras-mutant acinar 
cell in this model, that would support this “encapsulation” hypothesis. It would also 
suggest that the initial waves of inflammation and fibrosis that promote acinar 
dedifferentiation, serve as a true wound-healing response to eradicate or isolate 
pathological cells that might be resistant to apoptosis. However, Kras-mutant cells may 
also signal to recruit bystander cells, which they require for their sustained proliferation 
and evolution. “Clusters” of ubiquitously Kras-mutant acinar cells may also be more 
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likely to form PanINs utilizing this bystander effect. A final and intermediate possibility 
is that Kras-mutant cells are initially restrained as PanINs until a catastrophic mitotic 
event, such a chromothripsis, causes immense mutational burden and imparts invasive 
potential on a Kras-mutant cell (Notta et al., 2016).  
Regardless of whether PanIN cells are derived exclusively from Kras-mutant 
cells, our work demonstrates that they must downregulate Ptf1a to undergo 
transformation. We go on to show that loss of Ptf1a hastens the development of invasive 
PDAC, suggesting that loss of this transcription factor a rate limiting step for the entire 
acinar-to-PanIN-to-PDAC sequence. This makes Ptf1a unique among pancreatic master 
transcriptional regulators, as recent studies suggest that other differentiation determinants 
have dual roles in PDAC. For example, Pdx1 is expressed at low levels in acinar cells and 
is required to suppress acinar cell reprogramming in the presence of oncogenic Kras (Roy 
et al., 2016). In stark contrast to Ptf1a, Pdx1 remains highly expressed in PanINs but 
switches its transcriptional targets to facilitate RAS signaling and maintain 
tumorigenicity (Krah et al., 2015; Roy et al., 2016). Additionally,  Nr5a2, a transcription 
factor that coordinates acinar-specific gene expression with Ptf1a during homeostasis 
(Holmstrom et al., 2011), also has a dual role in PDAC: it initially restrains acinar cell 
transformation, but is later re-expressed in PDAC cells to drive proliferation (Benod et 
al., 2011; Flandez et al., 2014; von Figura et al., 2014). The unique role for each 
transcription factor underscores the importance of understanding how differentiation 
programs may influence cellular phenotype at different cancer stages. Taken together, 
these studies also suggest that reactivation of Ptf1a, but not Pdx1, may hold promise as a 
therapeutic strategy in PDAC.  
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 As PanINs and PDAC originate from acinar cells (Bailey et al., 2015; Habbe et 
al., 2008; Ji et al., 2009; Kopp et al., 2012), but do not express Ptf1a (De La et al., 2008; 
Krah et al., 2015), it will be important to determine the mechanism by which this gene is 
silenced. Since reactivation of Ptf1a and other components of the PTF1 transcriptional 
complex holds promise in preventing or re-differentiating PanINs/PDAC (Kim et al., 
2015), understanding this mechanism could provide novel therapeutic approaches. 
Beginning in late embryonic development and continuing through homeostasis in adults, 
the PTF1 transcriptional complex (composed of Ptf1a, E proteins, and Rbpj-L) maintains 
Ptf1a expression through an autoregulatory transcriptional loop, which requires access to 
a highly conserved 5’ autoregulatory enhancer (Masui et al., 2008). While mutations in 
the Ptf1a gene are not observed in human PDAC, mutations in this enhancer, which is 
located 13-15 kb upstream up the transcriptional start site, may not be picked up by 
whole exome sequencing. To test whether this intact enhancer element is required to 
prevent Kras-mediated transformation, the Ptf1a binding site could be mutated or deleted 
using CRISPR/CAS9. In collaboration with the MacDonald lab, Dr. Jane Johnson 
(University of Texas, Southwestern Medical Center) has recently engineered mice with 
such a deletion (unpublished correspondence). It will be interesting to cross these mice 
onto a KrasG12D background and determine whether deletion/mutation of this enhancer 
has the same effect as Ptf1a gene deletion (Krah et al., 2015). Additionally, oncogenic 
Kras signaling has been shown to promote the methylation and transcriptional repression 
of tumor suppressor genes, conferring a further growth advantage to colon cancer cells 
(Serra et al., 2014; Wajapeyee et al., 2013). If mutation of the autoregulatory is ruled out, 
could this mechanism of methylation be invoked in silencing the Ptf1a transcriptional 
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network during PDAC initiation? 
 The Ptf1a transcriptional network could also be silenced by changes in the 
transcriptional landscape of transforming acinar cells, promoted by stimulated oncogenic 
Kras. For example, oncogenic Kras may alter the balance of key transcription factors, 
such as Ptf1a and Sox9, to promote a duct-like gene expression profile. To determine 
whether Kras-mediated transformation alters chromatin accessibility, our lab is currently 
performing ATAC-seq on isolated KrasG12D-expressing acinar cell clusters and 
metaplastic ductules derived from those same clusters in an acinar suspension system 
(Buenrostro et al., 2013). We hypothesize that the Kras-induced chromatin 
rearrangements make Ptf1a and other key network components inaccessible for 
transcription. Sox9, which is upregulated when Ptf1a is deleted (Chapter 3), could 
facilitate a transcriptional switch to ductal gene expression (Kopp et al., 2012; Krah et al., 
2015). As we have previously demonstrated that decreased Ptf1a gene dosage sensitizes 
acinar cells to oncogenic transformation (Krah et al., 2015), it is easy to image that an 
attenuation of the autoregulatory loop described above would lead to rapid silencing of 
Ptf1a and its other acinar-specific targets. 
 While the above future direction focus on the cell-autonomous consequences of 
Kras mutation and Ptf1a loss, we provide substantial evidence that loss of Ptf1a alters the 
surrounding microenvironment. Loss of Ptf1a alone allows for the robust upregulation of 
several fibroinflammatory pathways, including stellate cell (pancreatic fibroblast) 
activation, dendritic cell maturation, and T-helper cell signaling – all of which have been 
implicated in PDAC development (Liou et al., 2015; Sherman et al., 2014; Zhang et al., 
2014). Consistent with these findings, loss of Ptf1a during acute pancreatitis allows for 
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persistence of the severe fibroinflammatory reaction to caerulein and an absence of 
epithelial regeneration (Krah et al., 2015). Additionally, the robust PanIN formation seen 
in KrasG12D; Ptf1a cKO pancreata is associated with leukocyte infiltration and fibroblast 
activation (Krah et al., 2015). Because this phenotype resembles that of KrasG12D mice 
subjected to caerulein-induced pancreatitis, we reasoned that inflammation might be 
driving both phenotypes (De La and Murtaugh, 2009; Guerra et al., 2007; Morris et al., 
2010a). Surprisingly, treatment with the corticosteroid, dexamethasone, produced 
opposite phenotypes in the Kras/caerulein and Kras/Ptf1a cKO mice.  
There are several future directions pertaining to these findings (see Discussion, 
Chapter 4). It will be interesting to test how depletion of different immune cell types 
effects both Kras/caerulein and Kras/Ptf1a cKO mice. Particularly interesting will be 
depletion of macrophages and dendritic cells, as these cells are closely associated with 
PanINs in all models of PDAC that we have studied and have been implicated in PanIN 
initiation (Lesina et al., 2011; Liou et al., 2015; Liou et al., 2013; Seifert et al., 2016). 
Since myeloid cells and macrophages can have polarized phenotypes, by which they 
either promote or inhibit cancer initiation and progression, it will be interesting to 
identify which macrophage-derived signals are received by transforming acinar cells. 
Could some populations of macrophages promote acinar regeneration? Could others 
promote PanIN formation, perhaps through IL-6 signaling (Lesina et al., 2011)? 
Identifying these signals, and how they interact with Kras mutant acinar cells, may hold 
great potential for inhibiting pancreatic disease going forward.  
Our work has greatly broadened the understanding PDAC initiation. While our 
understanding of disease initiation has greatly expanded over the past 10 years, clinical 
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outcomes have not significantly improved, despite advances in targeted therapy and 
immunotherapy. Further understanding of cell-autonomous changes in acini, and how 
those changes influence the surrounding microenvironment, should enhance our ability to 
form treatments that influence multiple aspects of PDAC earlier in the disease process. 
With a multitargeted approach, I believe that we will be able to impede disease 
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Figure 6.1. Overall model. In Chapter 3 (left side of diagram), I demonstrate that loss of 
Ptf1a is sufficient to induce acinar cell reprogramming, upregulate the ductal 
transcription factor Sox9, and produce a PDAC-like gene expression profile that sustains 
RAS signaling in human cancer cells. Consequently, Ptf1a-deficient cells are extremely 
sensitive to KrasG12D –mediated oncogenic transformation. In Chapter 4 (top of diagram), 
I propose that there are two distinct inflammatory waves during PDAC initiation: one that 
is primarily predominantly T-cells and is responsible to acinar cell reprogramming, and 
another that is macrophage derived that promotes bona fide PanIN formation. In Chapter 
5, I show that Ptf1a mediates a novel tumor suppressor mechanism, that is independent of 
p53 loss. Consequently, KPC (Kras, p53, Cre) mice with Ptf1a deleted from acini, 
succumb much more rapidly to PDAC than littermate KPC mice. Finally, I show that 
reintroduction of Ptf1a into established PanINs is sufficient to revert them the amylase-
positive acinar cells in vivo. This is among the first studies to demonstrate the plasticity 
of preoncogenic cells, and thus opens a new paradigm for solid tumor prevention and 
treatment.   
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